Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2026)
Vir Biotechnology (VIR) posted Income from Continuing Operations of 125695000.0 for Q1 2026, down 192.84% sequentially from 42923000.0 in Q4 2025, and down 3.91% YoY from 130809959.78 in Q1 2025.
Powered by 
Analysis
Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Income from Continuing Operations for 9 years, with the latest figure at 125695000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 3.91% year-over-year to 125695000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 442717000.0 (up 23.36% YoY) and the FY2025 annual result came in at 437987000.0, up 16.09% from the prior year.
- Income from Continuing Operations eased to 125695000.0 in Q1 2026 per VIR's latest filing, from 42923000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 518621000.0 in Q1 2022 and troughed at 213717000.0 in Q3 2024.
- A 5-year average of 69701294.12 and a median of 115973000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 407.04% in 2022, down 223.75% in 2022.
- Over 5 years, Income from Continuing Operations stood at 101603000.0 in 2022, then dropped by 14.14% to 115973000.0 in 2023, then grew by 9.82% to 104589000.0 in 2024, then surged by 58.96% to 42923000.0 in 2025, then tumbled by 192.84% to 125695000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 125695000.0, 42923000.0, and 163141000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Vir Biotechnology | 1.93 Bn | 1.93 Bn | 238.95 Mn | 80.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80.08 Mn |
| Mar 31, 2026 | -125.70 Mn |
| Dec 31, 2025 | -42.92 Mn |
| Sep 30, 2025 | -163.14 Mn |
| Jun 30, 2025 | -110.96 Mn |
| Mar 31, 2025 | -120.97 Mn |
| Dec 31, 2024 | -104.59 Mn |
| Sep 30, 2024 | -213.72 Mn |
| Jun 30, 2024 | -138.38 Mn |
| Mar 31, 2024 | -65.28 Mn |
| Dec 31, 2023 | -115.97 Mn |
| Sep 30, 2023 | -163.41 Mn |
| Jun 30, 2023 | -194.78 Mn |
| Mar 31, 2023 | -140.96 Mn |
| Dec 31, 2022 | -101.60 Mn |
| Sep 30, 2022 | 175.31 Mn |
| Jun 30, 2022 | -76.49 Mn |
| Mar 31, 2022 | 518.62 Mn |
| Dec 31, 2021 | 525.25 Mn |
| Sep 30, 2021 | 110.43 Mn |